Figure 4From: Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies Flow cytometric analysis of WSU-WM xenograft tumors. A. Phenotype of tumor cells in control (untreated) and following rituximab therapy, B. CD20 expression in residual tumors removed at days 7 and 9 post completion of RTX therapy compared with day of completion of therapy (day 0) and with tumors of untreated animals (untreated).Back to article page